A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab

NCT05304130 · clinicaltrials.gov ↗
PHASE1
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions

Conditions

Interventions

Sponsor

GlaxoSmithKline